This is one of the reasons why they are also gaining popularity as a weight management tool
Available Preparations In the UK, several GLP-1 receptor agonists are licensed and available through the NHS, including: Semaglutide (Ozempic, Wegovy, and oral Rybelsus) Dulaglutide (Trulicity) Liraglutide (Victoza, Saxenda) Exenatide (Byetta, Bydureon) Lixisenatide (Lyxumia) Most are administered via subcutaneous injection, with dosing frequencies ranging from twice daily to once weekly, depending on the specific formulation
Presented for research literature review only Bisseling JG et al
Combining liraglutide therapy with exercise further enhanced outcomes, resulting in greater weight loss, improved insulin sensitivity, and better cardiovascular fitness than either intervention alone (36)
Although SGLT-2 inhibitors and GLP-1 receptor agonists do not increase the risk of severe hypoglycemia, SGLT-2 inhibitors increase the risk of genital infections, and GLP-1 agonists have gastrointestinal adverse effects, especially at initiation and with high doses
